FINWIRES · TerminalLIVE
FINWIRES

Elevra Lithium Posts Higher Spodumene Concentrate Production in March Quarter; Shares Reach Over Two-Year High

-- Elevra Lithium's (ASX:ELV) spodumene concentrate production from its North American Lithium operation in Canada rose to 47,332 dry metric tonnes (dmt) in the March quarter from 43,261 dmt during the same period last year, according to a Thursday filing with the Australian bourse.

Spodumene concentrate sales were 55,526 dmt at an average realized selling price of $1,453 per dmt, up from 27,030 dmt at an average realized selling price of $710 per dmt in March 2025, the filing said.

The company reaffirmed its fiscal 2026 production guidance of 180,000 dmt to 190,000 dmt and sales guidance of 170,000 to 190,000 dmt, subject to the fulfillment of the shipping schedule, per the filing.

Shares rose about 2% in recent Thursday trade and earlier reached their highest since November 2023.

Related Articles

Asia

American Tungsten & Antimony Joins US Defense Supply Chain Consortium; Shares Up 12%

American Tungsten & Antimony (ASX:AT4) has joined the US Defense Industrial Base Consortium (DIBC), gaining access to US defense programs and advancing its antimony and tungsten strategy amid a growing focus on secure domestic critical mineral supply chains, according to a Friday Australian bourse filing.The company, through the consortium, gains access to Department of War programs, funding opportunities, and defense partnerships to advance domestic processing and strengthen supply chains in line with national security priorities, per the filing.The company also stated that over 50 DIBC-related projects have already secured about $410 million in funding, including roughly $39 million this year, highlighting strong government support, the filing said.The company will host a government-level critical minerals event in Utah on May 15, bringing together senior US officials, state leaders, and industry stakeholders, the filing added.The company's shares rose 12% in recent Friday trade.

$ASX:AT4
Asia

EBR Systems Receives Priority Review Determination From Therapeutic Goods Administration; Shares Up 7%

EBR Systems (ASX:EBR) received priority review determination from the Therapeutic Goods Administration for the WiSE System, according to a Friday filing with the Australian bourse.The WiSE System is a cardiac device capable of pacing the heart without a lead.The determination provides an accelerated pathway for the device to be included on the Australian Register of Therapeutic Goods, the filing said.Shares rose 7% in morning trade on Friday.

$ASX:EBR
Asia

Star Sports Medicine Launches Up to HK$830 Million Hong Kong IPO

Star Sports Medicine (HKG:1609) launched its Hong Kong initial public offering on Friday, seeking to raise about HK$829.6 million from the deal.The China-based medical device company is offering 8.4 million H-shares at an offer price of HK$98.50 per share, according to a Hong Kong bourse filing.The offering comprises 842,200 shares for Hong Kong investors and 7.6 million shares for international investors, subject to reallocation.The Hong Kong public offering closes on April 29, with allocation results due by May 4, ahead of the company's planned trading debut on May 5.Net proceeds will be used mainly to expand production capacity and enhance manufacturing efficiency, as well as support research and development.The funds will also be used to strengthen sales and marketing capabilities, expand global distribution, and for working capital and general corporate purposes.CITIC Securities (Hong Kong) and CCB International Capital are acting as joint sponsors.CLSA and CCB International Capital are serving as overall coordinators, alongside China Galaxy International Securities and CMBC Securities, and are also acting as joint bookrunners.Futu Securities International (Hong Kong), Open Securities, Orient Securities (Hong Kong), and Zheshang International Financial are acting as joint bookrunners and joint lead managers.

$HKG:1609